Mannkind Corp. (MNKD)
NASDAQ:MNKD
MNKD Stock Chart & Stats
$2.61
-$0.05(-0.80%)
At close: 4:00 PM EST
$2.61
-$0.05(-0.80%)
Day’s Range― - ―
52-Week Range$2.23 - $6.51
Previous CloseN/A
Volume434.88K
Average Volume (3M)8.14M
Market Cap
$804.14M
Enterprise Value$1.20B
Total Cash (Recent Filing)$171.35M
Total Debt (Recent Filing)$473.38M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 13, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding308,100,430
10 Day Avg. Volume5,282,042
30 Day Avg. Volume8,137,889
Financial Highlights & Ratios
PEG Ratio-3.69
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue3.45
Enterprise Value/Gross Profit4.51
Enterprise Value/Ebitda23.13
Forecast
1Y Price Target
$7.08Price Target Upside171.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$451.35M
Bulls Say, Bears Say
Bulls Say
Labeling And DosingAn updated dosing conversion on the Afrezza label is expected to improve dosing accuracy, reduce under‑dosing, and encourage patients to switch from injections or insulin pumps to inhaled insulin, supporting sales growth.
Regulatory Approval (pediatrics)Initiation and first‑patient enrollment in a pediatric trial for Afrezza, together with an FDA label update, advance the path to pediatric approval and could expand the product's commercial population.
Revenue Diversification And PipelineAcquisition of scPharma and internal development of an inhaled nintedanib candidate broaden revenue sources beyond a single royalty and create potential new revenue streams if clinical programs and partnerships progress.
Bears Say
Partner Competition And RoyaltiesUnited Therapeutics' introduction of a soft mist inhaler and a new oral prostacyclin may reduce demand for the licensed dry powder formulation, creating downside pressure on royalty income.
Real‑world Efficacy And Adoption RiskReal‑world reports linking reduced Afrezza effectiveness to under‑dosing could limit clinician confidence and patient uptake unless dosing guidance and provider training successfully address correct use.
Royalty And Valuation UncertaintyUncertainty about how competing treatments and formulation changes will affect Tyvaso dry powder inhaler royalties increases valuation risk for the company.
MannKind News
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $2.23 and its highest was $6.51 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $804.14M.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is May 13, 2026 which is in 33 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Feb 26, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0.017 by -$0.067.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is -0.01.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 308,100,430 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of -$0.05 in its last earnings report, missing expectations of $0.017. Following the earnings report the stock price went down -7.429%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.08 (171.26% Upside)
$7.08 (171.26% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 26.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $259.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.99%
12-Months-Change
Fundamentals
Return on Equity
-11.21%
Trailing 12-Months
Asset Growth
101.14%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a predominantly positive outlook: the company reported record quarterly and annual revenues, strong and accelerating growth for newly acquired Furoscix, Afrezza commercial momentum with regulatory and label progress (including pediatric PDUFA), predictable royalty and supply cash flows from Tyvaso DPI, and advancement of a potentially high-impact MNKD-201 program. Near-term challenges include integration and commercialization investments that pressure margins in 2026, seasonality for Furoscix in Q1, regulatory execution risks around PDUFAs, and some uncertainty around future supply volumes from United Therapeutics. Overall, the positives (diversified growth drivers, clear near-term catalysts, and improving adjusted profitability) outweigh the manageable risks called out on the call.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$7.08
▲(171.26% Upside)
Technical Analysis
Ownership Overview
2.98% Insiders
11.25% Mutual Funds
15.17% Other Institutional Investors
55.02% Public Companies and
Individual Investors